Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers.
Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
Patients who have a record of intestinal resection in their medical history.
Patients with a medical background of irritable bowel syndrome.
Patients with a history of inflammatory bowel disease.
Patients who regularly take anti-diarrheal medications before commencing radiotherapy.